J&J pulls 200K Motrin bottles on plastic particles; Onyx investors sue over Amgen sale;

@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma

@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: The DoJ probes GSK for U.S. bribery violations in China, Reuters reports. FCPA probe of entire industry. Story | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) recalled 200,000 bottles of Motrin Infants Drops because they might have been contaminated with tiny particles of plastic. Report

> Onyx Pharmaceuticals ($ONXX) investors sued the company, claiming its planned $10.4 billion sale to Amgen ($AMGN) favors the buyer and that conflicts of interest "infected" the deal. Report

> Sagent Pharmaceuticals ($SGNT) announced a 4.44 million-share offering, comprising 3.38 million shares offered by the company and 1.06 million offered by selling shareholders. Report

> Former GlaxoSmithKline ($GSK) chairman Sir Richard Sykes now chairs a company, NetScientific, that plans to go public in the U.K. later this month. Report

> The Association of the British Pharmaceutical Industry's watchdog panel said Gedeon Richter breached its promotional code of practice. Report

Medical Device News

@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev

@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce

@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Baxter finally closes $4B Gambro deal, eyes dialysis dominance. More

> CeQur's insulin pump draws $27M Series B. Article

> Sapheon nails down $19.8M for varicose vein treatment. Report

Biotech News

@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech

@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce

@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride

@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce

> DRI Capital gains $1.45B in fresh firepower for drug royalty deals. Report

> Biogen fronts $100M to add Isis R&D pact on neurological diseases. Story

> Crowded field of PhIII COPD contenders will compete for blockbuster market. Article

CRO News

> Novella shuffles execs as Quintiles deal pends. Item

> AMRI chief stepping down at year's end. News

> Patheon posts Banner quarter on 30% sales surge. Article

> Covance teams with Indiana U. for early trials. Story

> Capsugel snaps up Bend with eye on oral formulations. More

Biotech IT News

> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report

> Texas biotech software outfit trumpets open source tools. Item

> Genentech backs development of video game for kids with cancer. More

> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story

> Accelrys scoops up Bay Area software firm for $15.3M. Article

And Finally... A combination of two common antiviral drugs could be useful against the respiratory virus emerging in the Middle East. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.